BioInvent International (STO:BINV) 24% confirmed ORR (including complete response) in heavily pretreated patients (n=25) with advanced ovarian cancer who received BI-1808 and KEYTRUDA - multiplying by ...

There are two major reasons why Merck isn't too reliant on Keytruda yet. First, the company has other products to count on to drive its sales. Most notably, Merck's vaccines lineup -- which includes ...

Moderna and Merck's combination therapy for skin cancer helped reduce risk of cancer spreading to another part of the body ...

TOKYO, Oct 1, 2019 - (JCN Newswire) - - Eisai and Merck & Co., Inc., Kenilworth, N.J., U.S.A. (NYSE: MRK), known as MSD outside the United States and Canada, announced final results from the full ...

While Keytruda is not currently known to interact with other drugs, supplements, foods, lab tests, or alcohol, it’s important to consult with your doctor and pharmacist about everything you’re taking ...

Merck & Co. has failed in an attempt to repeat Keytruda’s metastatic head and neck cancer success in locally advanced disease. But experts still see reasons to keep their hopes up for the drug in ...

Full accrual of 21 checkpoint-naïve melanoma patients No safety concerns identified; no significant overlap of toxicities 95% 12-month OS rate; 100% 12-month DSS rate; Median PFS of 11.7 months 10% CR ...

The FDA approved Keytruda for NSCLC based on several clinical trials. Keytruda was studied in people whose NSCLC had spread to other parts of the body (metastatic) and who had received no prior ...

BioInvent International (STO:BINV)24% confirmed ORR (including complete response) in heavily pretreated patients (n=25) with advanced ovarian cancer who received BI-1808 and KEYTRUDA - multiplying by ...